Genome- and proteome-based research is generating a significant
increase in the number of available drug targets. Correspondingly
there is an increasing need for novel, diverse compounds,
particularly based on natural compounds, as screening resource. The
purpose of the Ernst Schering Research Foundation Workshop 51 was
to provide a forum for an open exchange on perspectives and
limitations of biocombinatorial synthesis and the significance of
this technology for future drug discovery in light of this
challenge. Experts from academia and industry provided
contributions covering: the significance of natural compounds for
state-of-the-art drug discovery; the underlying basic principle for
the biosynthesis of highly complex compounds; and the scope and
limitations of combinatorial biosynthesis regarding formation,
identification, optimisation, isolation and manufacturing of novel
biologically active entities.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!